Trending News

#Cell and gene therapy #Cell and Gene Therapy Catapult #Life sciences

New data shows promising cell and gene therapy industry across the UK  

The Cell and Gene Therapy Catapult (CGT Catapult) has published new data in their 2021 Cell and Gene Therapy GMP manufacturing report and 2021 UK cell and gene therapy skills demand report. These reports highlight the continued growth across the UK’s Advanced Therapy Medicinal Product (ATMP) manufacturing capacity and… Read More

#News #Trending News

This week in drug discovery (22-26 November) 

News round-up by DDW’s Megan Thomas for 22-26 November   As the year draws to a close, looking both back and forward to identify and anticipate trends and market behaviour is important. This week, DDW’s Megan Thomas has rounded up five stories which identify interesting and impactful trends and analysis with… Read More

#News #Trending News

#CAR-T #DNA #Drug development #Drug discovery #Podcast #Synthetic biology

Podcast: Building on current drug discovery methods

This is the latest episode of the free DDW podcast, “Building on current drug discovery methods”. It covers two narrated article written for Volume 22, Issue 2 – Spring 2021 of DDW and read aloud by Megan Thomas. The articles are called “The new synthesis: How synthetic DNA technology is… Read More

#News #Trending News

#CAR-T #Flow Cytometry #Tumour #Webinar

How to identify and evaluate new tumour markers 

Major advances have been achieved in targeted immunotherapy with significant clinical benefits for patients. However, on-target/off-tumour toxicity is still a major concern, which highlights the clinical need for better targets to improve the safety profile of immunotherapies.   On-target/off-tumour toxicity is mainly based on the expression of tumour-associated… Read More

#News #Trending News

#Cancer research #Drug therapy #Immunotherapy

Agreement to launch breakthrough cancer immunotherapy treatment

Terumo Blood and Cell Technologies and Immunicom have signed a co-commercialisation agreement to help advance a cancer therapy that selectively removes immune inhibitors from a patient’s bloodstream.   What will this achieve?  This potentially enables the patient’s immune system to more effectively attack cancer tumours. In contrast to immunotherapy pharmaceuticals… Read More

#Cancer Research #News #Trending News

#Drug development #Drug discovery #GlobalData #siRNA #Therapeutics

Chinese pharma companies eye strategic alliances for therapeutics

The overall potential of siRNA-based therapeutics has attracted Chinese pharma companies to tap opportunities and bring promising innovative therapies across the globe, according to reporting by GlobalData. Against this backdrop, the Chinese pharma companies have increased their focus towards the siRNA pipeline through strategic alliances.  China pharma… Read More

#News #Trending News

Human brain
#Drug development #Drug discovery #Healthcare #Neuroscience #Pharmaceuticals

NICE approves drug which treats EDS caused by narcolepsy 

Jazz Pharmaceuticals’ Sunosi (solriamfetol) has been issued a positive Final Appraisal Document (FAD) from the National Institute for Health and Care Excellence (NICE), recommending the drug for adults with excessive daytime sleepiness (EDS) caused by narcolepsy.1  When is solriamfetol needed?  Solriamfetol is recommended as an option for treating EDS… Read More

#News #Trending News

#Clinical trials #Covid-19 #GlobalData

UK falls behind other countries in clinical trial activity 

While trial activity has since recovered to pre-Covid-19 pandemic levels in Australia and the US, the UK remains behind, according to reporting by Andrew Hillman, healthcare and pharmaceuticals data journalist at GlobalData.  Hillman explained that the UK commenced 18% fewer commercial trials during the first three quarters of 2021 than… Read More

#Covid-19 #News #Trending News

#Immunology / Virology & Vaccines #Life sciences

Azenta to distribute vaccines to the US Department of Defense 

Brooks Automation’s newly branded Azenta Life Sciences has been contracted by QTC Management to provide the storage and distribution of vaccines to the US Department of Defense.  Context  In early 2021, QTC was awarded the Reserve Health Readiness Program III contract, under which they… Read More

#News #Trending News

#Data #Drug development #Drug discovery #Genomics #Research study #Tuberculosis

Largest ever global TB study identifies genetic causes of drug resistance 

The Comprehensive Resistance Prediction for Tuberculosis International Consortium (CRyPTIC) research project has reportedly collected the largest ever global dataset of clinical M. tuberculosis samples from across the world consisting of 15,211 samples from 27 countries on five continents.  Using a new quantitative test for drug resistance and… Read More

#News #Trending News

#Cell therapy #Drug development #Drug discovery #Immunology

Bone marrow backup needed to tackle respiratory infections 

Scientists at the Francis Crick Institute have found how the immune system triggers an ‘emergency’ dendritic cell response during infection, with dendritic cells at the site of infection being reinforced by new cells which travel from the bone marrow.   Dendritic cells have an important role in the… Read More

#News #Trending News

#Biotechnology #CAR-T #Tumour #Webinar

Using ultra high-content imaging for target discovery for CAR T cell therapy 

In this free webinar, Dr. Christoph Herbel presents a newly developed workflow which combines flow cytometry–based screenings with high-parameter imaging to identify and validate new tumour markers in an unbiased approach.   The event, Kill the tumour, spare the healthy tissue. Ultra high-content imaging enables target discovery for CAR T cell therapy, was hosted by DDW and supported by Miltenyi Biotec.  It… Read More

#News #Trending News

#Collaboration #Covid-19 #Research

This week in drug discovery (15-19 November) 

News round-up by DDW’s Megan Thomas for 15-19 November  As the world emerges from the Covid-19 pandemic, DDW’s Megan Thomas has rounded up five stories which show how the drug discovery industry has used what it has learnt over the last two years to innovate for the… Read More

#News #Trending News

New investigational synthetic biotic for treatment of homocystinuria

Synlogic and Ginkgo Bioworks have nominated SYNB1353, an investigational synthetic biotic medicine for the treatment of homocystinuria (HCU).   SYNB1353 is the first product developed through a research collaboration between Synlogic and Ginkgo and the first investigational medicine developed on Ginkgo’s platform to enter IND-enabling studies. Synlogic expects to file an investigational new drug (IND)… Read More

#News #Trending News